Provided by Tiger Trade Technology Pte. Ltd.

Cogent

9.09
-0.2400-2.57%
Post-market: 9.05-0.0400-0.44%19:30 EDT
Volume:2.17M
Turnover:19.39M
Market Cap:465.55M
PE:-9.65
High:9.37
Open:9.20
Low:8.60
Close:9.33
52wk High:45.69
52wk Low:8.60
Shares:51.22M
Float Shares:45.32M
Volume Ratio:1.01
T/O Rate:4.79%
Dividend:0.08
Dividend Rate:0.88%
EPS(TTM):-0.9421
EPS(LYR):-3.8009
ROE:-721.50%
ROA:-1.24%
PB:-13.64
PE(LYR):-2.39

Loading ...

Cogent Communications Q1 Adjusted Ebitda USD 70.183 Million VS. Ibes Estimate USD 73.5 Million

THOMSON REUTERS
·
May 04

Cogent Communications Reports First Quarter 2026 Results

THOMSON REUTERS
·
May 04

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

Cogent Communications Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview

Reuters
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

Earning Preview: Cogent Communications Holdings, Inc. revenue is expected to decrease by 3.60%, and institutional views are cautious

Earnings Agent
·
Apr 27

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
Apr 21

A Look At Cogent Communications Holdings’s Valuation After Its Recent Share Price Rebound

Simply Wall St.
·
Apr 20

Cogent Communications Weighs Liquidity Risks Against Valuation Discount

Simply Wall St.
·
Apr 19

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

GlobeNewswire
·
Apr 17

Cogent to host first-quarter earnings call May 4

Reuters
·
Apr 15

Cogent Communications to See 'Soft' Q1, 'Strong Rebound' in H2, Oppenheimer Says

MT Newswires Live
·
Apr 08

Cogent Biosciences submits bezuclastinib new drug application to the FDA

TIPRANKS
·
Apr 01

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire
·
Apr 01

Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers

TIPRANKS
·
Mar 28

Cogent Communications Holdings Inc. Announces Annual Stockholders Meeting

Reuters
·
Mar 21

Cogent Communications Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Mar 18

Cogent price target lowered to $22 from $23 at RBC Capital

TIPRANKS
·
Mar 18

RBC Lowers Price Target on Cogent Communications Holdings to $22 From $23, Keeps Sector Perform Rating

MT Newswires Live
·
Mar 18

Cogent Comms (CCOI) Gets a Hold from RBC Capital

TIPRANKS
·
Mar 18